Societal CDMO Reports Third Quarter 2023 Financial Results
Recorded Q3 Revenue of $23.6 Million
Signed Multiple New Business Agreements with New and Existing Customers
Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million
Related news for (SCTL)
- Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
- Societal CDMO Reports Inducement Grants for New Staff
- Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
- Societal CDMO Reports Inducement Grants for New Staff